Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-DIMERPA in Mixed Hyperlipidemia
NCT07223658Phase 2Recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in mixed hyperlipidemia (2 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events. Started Dec 2025; status: recruiting.
02
Conditions
mixed hyperlipidemia
Beyond the preview
Go deeper on NCT07223658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223658.